Testimonials

Since Tri-Solfen^® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Country	Species	Patent
Australia	Sheep	Granted
Australia	Horses, Dogs, Lab animals	Granted
Australia	Cattle	Granted
Australia	Humans	Granted
New Zealand	Sheep, Cattle	Granted
New Zealand	Horses, Dogs, Lab animals	Granted
EU	Humans	Granted
EU	Pig, Sheep, Cattle	Granted
USA	Dogs, Horses, Lab animals	Granted
USA	Humans	Granted
USA	Pig, Sheep, Cattle	Granted
Canada	Horses, Dogs, Lab animals	Granted
Canada	Cattle, Pig	Granted
Canada	Humans	Granted

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Tri–Solfen^®

Tri-Solfen^® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen^® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen^® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.

Press Release

Australian Research Company Animal Ethics Secures UK investment partner

April 3, 2017

Animal Ethics Pty Ltd (Animal Ethics) secures cornerstone investor with 33% of its share capital purchased by FTSE 250 company Dechra Pharmaceuticals PLC.

The investment includes a global license agreement (excluding Australia and NZ) for the Animal Ethics pain mitigation and wound treatment technology

Tri-Solfen^®, and will accelerate Animal Ethics objective to register Tri-Solfen^® in major international markets, such as the EU and USA.

Tri-Solfen^® has proven to be highly successful in Australia, and is registered as an over-the-counter product for the reduction of pain in lambs and calves undergoing routine surgical procedures, such as castration, tail-docking and disbudding. To date the leading animal welfare technology has treated over 70 million animals.

The global market potential for Tri-Solfen^® is estimated to be in excess of AUD $350 million per year for the treatment of routine on farm procedures in calves, lambs and piglets.

“This is a great result for our Australian based research and development company, world-wide consumers are now demanding best animal welfare practices in food and fibre production” said Allan Giffard, managing director of Animal Ethics. “Dechra is a leading global pharmaceutical company that has also recognised the social impact this is creating, and through their investment will assist Animal Ethics in providing a practical and cost efficient animal welfare solution for livestock industries globally. This new partnership with Dechra is a major breakthrough for our company.’’

– Ends –

About Medical Ethics

Medical Ethics is a commercial and development stage company focused on pain mitigation in wounds for humans and animals.

Through our proven patent protected platform technology, we have identified a transformational way of mitigating pain and minimising suffering associated with wounds.

About Tri-Solfen^®

Tri-Solfen^® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen^® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen^® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000

Email alerts